Global Blood Therapeutics reports Q4 earnings, summarizes upcoming catalysts
Global Blood Therapeutics' (GBT) novel sickle cell disease drug, Oxbryta, has officially hit the market, netting a mere $2M in revenue. Meanwhile, R&D costs have nearly doubled in the last year. SG&A costs have nearly tripled! Such is expected when launching a drug, but the question is always, "to what extent is it tolerable?"
Global Blood hopes, following a non-dilutive loan, to be cash flow positive before having to resort back to dilution again:
Entered into a $150 million loan agreement with funds